Object

This publication is protected and available only for logged users.
This publication is protected and available only for logged users.

Title: The value of Cancer Antigen 125 (CA-125) and endovaginal ultrasonography for diagnostics and treatment of malignant ovarian tumour

Abstract:

The battle with the ovarian cancer is now easier thanks to ultrasonography, which is constantly being improved. Lately, its possibilities have been enlarged on the Doppler Effect that helps locate a tumour, as well as estimate its blood flow. Second way of assessment is the concentration of the tumour marker CA-125 in the blood. However, previous data, especially those concerning the usefulness of the methods for prediction of ovarian tumour character and for monitoring the cancer process after treatment, are very diverse. Therefore, the aim of the present research is to define: 1. usefulness of the endovaginal ultrasonography and the Doppler technique for detection and estimation of ovarian cancer tumours and their relapse after treatment. 2. acting of CA-125 level in the blood serum according to the grade of ovarian cancer progress by Figo, the grade of diversity and the histological image. 3. acting of CA-125 level in the blood serum after surgery treatment, during the process of chemotherapy and after it. 4. defining the CA-125 and the endovaginal ultrasonography sensitivity for detection of the cancer process relapse. 5. total assessment of endovaginal ultrasonography and CA-125 level in the blood serum for diversity of ovarian cancer and detection of the relapse after treatment. The aim has been realised on the basis of the research material that included 145 women, diagnosed and treated at Gynecology and Oncology Clinic, from 1998 to 2003, due to pathological changes in ovaries. This number includes 104 cases of malignant tumour (studied group), and 41 cases of benign tumour (comparative group). Basing on carried out tests and clinical observations, the following conclusions have been drawn: 1. endovaginal ultrasonography of ovarian tumours enables to pre-assess their diversity, which in 70% of cases coincides with the final result of histology test. If supplemented with Doppler technique of blood flow in tumour, the ultrasonographic estimation of tumour is improved on 10%. Endovaginal ultrasonography should be supplemented with ultrasonography through the abdominal wall in order to detect possible metastasis in abdominal organs. 2. the cancer marker CA-125 level in the blood serum, while treated as a separate method, has a limited value for assessing the type of ovarian tumours. However, if the marker level is raised significantly due to suspicion of malignant tumour by ultrasonographic test supplemented with Doppler technique, it enables to pre-assess malignant ovarian tumours, which is proven in almost 100% by the histology test. 3. the cancer marker CA-125 level in the blood serum in the cases of malignant ovarian tumour depends on tumour classification values, histological image and grade of cancer diversity. 4. when, after surgery treatment, the CA-125 level in the blood serum is normalised, it proves that the operation was extended and life expectancy of a patient is improved, as well as the percent of patients living through 5 years. 5. the fall of the CA-125 level in the blood serum observed during the chemotherapy till a normal level, proves that the response for chemotherapy has been positive. 6. control ultrasonographic test after a finished treatment (surgery and chemotherapy) allows to detect only about 60 % of relapses and survived tumour’s origin sites; computed tomography, and, especially, nuclear magnetic resonance improve this result; however, a negative result of these tests does not prove the lack of cancer process. 7. the most sensitive marker for the detection of relapses and an active cancer process is the assessment of concentration of CA-125 in the blood serum. 8. it appeared that if the CA-125 is raised above a normal level after the treatment is finished, it is the first signal of re-activation of a cancer process and it can be a few months ahead the appearance of changes possible to detect by graphic tests.

Level of degree:

2 - studia doktoranckie

Degree discipline:

onkologia ; ginekologia

Degree grantor:

Wydział Lekarski

Promoter:

Antoni Basta

Date issued:

2008

Format:

application/pdf

Identifier:

oai:dl.cm-uj.krakow.pl:856

Call number:

ZB-109396

ControlNumberVIRTUA:

click here to follow the link

Access rights:

tylko w bibliotece

Location of original object:

Biblioteka Medyczna Uniwersytetu Jagiellońskiego - Collegium Medicum

Object collections:

Last modified:

Nov 18, 2019

In our library since:

Nov 21, 2012

Number of object content hits:

9

Number of object content views in PDF format

9

All available object's versions:

http://dl.cm-uj.krakow.pl:8080/publication/856

Show description in RDF format:

RDF

Show description in OAI-PMH format:

OAI-PMH

Edition name Date
ZB-109396 Nov 18, 2019
×

Citation

Citation style:

This page uses 'cookies'. More information